Antifungal Prophylaxis in Pediatric Acute Leukemia
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Hypothesis:Oral Voriconazole will be as effective as intravenous Amphotericin B as antifungal
prophylaxis in induction of acute leukemia (ALL, AML) in pediatric patients, with less
toxicity and more convenience.
Phase:
Phase 3
Details
Lead Sponsor:
All India Institute of Medical Sciences, New Delhi
Treatments:
Amphotericin B Antifungal Agents Liposomal amphotericin B Miconazole Voriconazole